MedPath

The European Paediatric Network for Haemophilia Management ( PedNet Registry)

Recruiting
Conditions
Factor VIII Deficiency
Factor IX Deficiency
Registration Number
NCT02979119
Lead Sponsor
PedNet Haemophilia Research Foundation
Brief Summary

Rationale:

Haemophilia is a rare disease; to improve knowledge international collaboration is needed. Well-defined clinical data will be collected from complete cohorts in order to prevent selection bias.

Objective:

To collect data on bleeding during neonatal period, endogenous (genetic) and exogenous (treatment-related) determinants of inhibitor development and long term outcome.

Detailed Description

Design: Multicenter Prospective Observational Birth Cohort Study

Population:

Patients with haemophilia A and B with FVIII/IX levels of \<1 to 25% born between 1-1-2000 and 1-1-2030.

Intervention:

No intervention; only documentation of patient characteristics and parameters of routine patient care and outcome

Main outcome parameters:

Outcome: clinically relevant inhibitor development, bleeding pattern and joint status on physical examination and imaging.

Determinants: baseline FVIII/IX levels, measurement of inhibitory antibodies, family history, FVIII/IX gene mutation, details on replacement therapy (according to each infusion for the first 50 treatment days, and annually thereafter) and surgeries.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

* No burden for the patients. Well-defined clinical data will be collected from the medical files. Participating in this registry will not change the number of visits to the clinic. All outcome parameters that are collected (including laboratory results) are part of routine clinical care.

* Direct benefit is not to be expected. However, the direct interaction between centres that treat patients with rare diseases improves both clinical care and will result in better guidelines and as such may provide indirect benefit.

* Multicentre participation: haemophilia is a very rare condition. Therefore, collecting data on a multi-centre observational cohort is the only way to study this specific population.

* The registry concerns young boys and girls with haemophilia and cannot be performed in older patients, as \>90% of inhibitors occur develop during the first 50 exposure days, and the results of prophylactic replacement therapy are highly dependent on the initiation of this treatment.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
4000
Inclusion Criteria
  • Diagnosed with Haemophilia A or B
  • Factor VIII/ IX activity of <1 to 25%
  • Complete records of Factor treatment and bleeds
  • Treated in one of the participating centres
Exclusion Criteria
  • Patients referred because of an inhibitor*
  • Informed consent not obtained

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of patients with antibody development to exogenous clotting factorsUntil patient reaches age of 18

Allo-antibodies against Factor VIII and IX; Blood test: measurement in Bethesda units (BU), positive according to local standards, for most labs \>0.5 BU

Secondary Outcome Measures
NameTimeMethod
Long term outcome of haemophilia on joint status using the Hemophilia Joint Health Score (HJHS) and MRI techniques.From diagnose every 5 years until patient reaches age of 18

Effect of different prophylactic regimen on bleeding and joint damage

Long term outcome different Immune Tolerance Induction (ITI) therapies in patients with inhibitor.From date first positive inhibitor titer preferably every 3 years until patient reaches age of 18

Effect of different ITI therapies on bleeding and joint damage. Joint damage is assessed using the HJHS and MRI.

Trial Locations

Locations (39)

Medical University of Vienna - Department of Paediatrics

🇦🇹

Vienna, Austria

Universitäts-Klinik für Kinder- und Jugendheilkunde

🇦🇹

Graz, Austria

Service of Pediatric Haematology University Hospital Leuven

🇧🇪

Leuven, Belgium

Division of Hematology/Oncology Hôpital St Justine

🇨🇦

Montréal, Canada

Division of Haematology/Oncology Hospital for Sick Children

🇨🇦

Toronto, Canada

Haemophilia Comprehensive Care Centre, Centre for Thrombosis and Haemostasis Children's University Hospital Brno

🇨🇿

Brno, Czechia

Department of Paediatric Haematology/oncology - University Hospital Motol

🇨🇿

Praha, Czechia

Service Hématologique Centre Regional Traitement d'Hemophilie Bicetre

🇫🇷

Le Kremlin Bicêtre, France

Service d'Hématologie Pédiatrique Hôpital Universitaire La Timone

🇫🇷

Marseille Cedex-05, France

Charité Campus Virchow Klinikum, Klinik für Pädiatrie m.S. Onkologie und Hämatologie

🇩🇪

Berlin, Germany

Centre de traitement des hémophiles Hôpital Universitaire Purpan

🇫🇷

Toulouse, France

Department of Internal Medicine, Hemophilia Treatment Center, Vivantes Klinikum im Friedrichshain

🇩🇪

Berlin, Germany

Klinik Bremen-Mitte Prof.-Hess-Kinderklinik

🇩🇪

Bremen, Germany

Institut für Experimentelle Hämatologie und Transfusionsmedizin Universitätsklinikum Bonn

🇩🇪

Bonn, Germany

University Hospital Frankfurt & Goethe University - Clinical and Molecular Hemostasis, Department of Pediatrics

🇩🇪

Frankfurt am Main, Germany

Hämophilie Zentrum Rhein Main

🇩🇪

Mörfelden-Walldorf, Germany

Dr. v. Haunersches Kinderspital University of Munich

🇩🇪

Munich, Germany

The National Hemophilia Center Sheba Medical Center, Tel Hashomer

🇮🇱

Ramat Gan, Israel

Haemophilia-Haemostasis Unit St. Sophia Children's Hospital

🇬🇷

Athens, Greece

Azienda Ospedaliero Universitaria Careggi

🇮🇹

Florence, Italy

Gaslini Hospital

🇮🇹

Genova, Italy

Centro Hospitalar São João, S. Imuno-hemoterapia

🇵🇹

Porto, Portugal

Van Creveld Kliniek University Medical Center Utrecht

🇳🇱

Utrecht, Netherlands

A. Bianchi Bonomi Hemophilia and Thrombosis Centre IRCCS Ca' Granda Ospedale Maggiore Policlinico

🇮🇹

Milano, Italy

Unitat Hemofilia Hospital Vall d'Hebron

🇪🇸

Barcelona, Spain

Hospital General Unidad de Hemofilia 1 Sur Hospitales Universitarios Virgen del Rocio

🇪🇸

Seville, Spain

Unidad de Coagulopatías Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Department of Pediatrics, Clinic of Coag. Disorders Karolinska Hospital

🇸🇪

Stockholm, Sweden

Unidad de Coagulopatias Congenitas Hospital Universitario la Fe

🇪🇸

Valencia, Spain

Lund University Hospital

🇸🇪

Malmo, Sweden

Birmingham Children's Hospital NHS Trust - Department of Haematology

🇬🇧

Birmingham, United Kingdom

Royal Hospital for Sick Children

🇬🇧

Edinburgh, United Kingdom

Department of Haematology Royal Hospital for Sick Children

🇬🇧

Glasgow, United Kingdom

Haemophila Center Great Ormond Street Hospital for Children

🇬🇧

London, United Kingdom

Dept of Paediatric Haematology Our Lady's Children's Hospital for Sick Children Crumlin

🇮🇪

Dublin, Ireland

Inselspital Bern, University Children's Hospital

🇨🇭

Bern, Switzerland

Children's Hospital Helsinki University Hospital

🇫🇮

Helsinki, Finland

Oslo University Hospital

🇳🇴

Oslo, Norway

Department of Pediatrics Århus Kommunehospital Skejby Sygehus

🇩🇰

Aarhus, Denmark

© Copyright 2025. All Rights Reserved by MedPath